Announced details
Phase 1/2 clinical trial in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes
The conference accepted the company's abstract on rogocekib and published the abstract.
An internationally renowned conference in the field of hematology. The 2026 Annual Congress will be held in Stockholm, Sweden.
Abstract No. EHA-3974
Fujisawa, Kanagawa Prefecture (the company's head office)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Abstract presented at the European Hematology Association (EHA) Annual Congress
| Item | Details |
|---|---|
| Names of Products / Services Covered | rogocekib（CTX-712） |
| Counterparty | European Hematology Association（EHA） |
| Counterparty overview | An internationally renowned conference in the field of hematology. The 2026 Annual Congress will be held in Stockholm, Sweden. |
| Relationship with the Company | The conference accepted the company's abstract on rogocekib and published the abstract. |
| Launch date | Poster presentation scheduled for 13 June 2026, 18:45–19:45 (CEST) |
| Applicable area | Phase 1/2 clinical trial in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes |
| Registration number and expiry date | Abstract No. EHA-3974 |
| Location | Fujisawa, Kanagawa Prefecture (the company's head office) |
| Source | Abstract presented at the European Hematology Association (EHA) Annual Congress |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company explained that the EHA Annual Congress is an internationally renowned conference in the field of hematology, and that the acceptance of the abstract reflects recognition by the international hematology community of rogocekib's scientific validity and progress in its clinical development.